Course Outline
Click on the links below to preview selected pages from this course.
- Coagulation Overview
- Coagulation Cascade Overview
- Pathways for Coagulation
- Pathways
- Extrinsic Pathway
- Intrinsic Pathway
- Common Pathway
- Fibrin Clot and Fibrinolysis
- The intrinsic pathway for coagulation begins with the activation of which of the following factors?
- The final common pathway begins with the activation of which of the following factors?
- Case Study #1
- Traditional and New Oral Blood Anticoagulants
- Traditional and New Oral Anticoagulants (NOACs)
- Traditional Blood Anticoagulants
- Traditional Anticoagulants
- Heparin inhibits the clotting of blood by neutralizing the effect of which of the following?
- Warfarin is an antagonist of which of the following vitamins?
- New Oral Anticoagulants (NOACs)
- New Oral Anticoagulants (NOACs)
- Thrombin Inhibitor
- Factor Xa Inhibitors
- Which of the NOACs impacts thrombin?
- Clinical Applications of Novel Oral Anticoagulants
- Laboratory Assessment
- The Gold Standard Assay
- "Front Line" Common Coagulation Tests
- Front Line Common Coagulation Tests
- Specific NOAC Testing Methods
- Impact of NOACs on Other Coagulation Assays of Importance
- Impact of NOACs on Other Coagulation Assays
- NOAC Impact on Antithrombin Activity and Activated Protein C Resistance
- NOAC Impact on Coagulation Factors and Fibrinogen
- NOAC Impact on Lupus Anticoagulants and Protein C/Protein S Activity
- Specimen Collection and Processing
- Specimen Collection and Processing
- A blood specimen from a patient receiving anti-Xa therapy can be stored for a maximum of how many hours after collection?
- After collection, a plasma specimen from a patient receiving NOAC therapy can be stored in a freezer for a maximum of how long?
- Interpretation of Test Results
- Prothrombin Time (PT)
- Activated Partial Thromboplastin Time (APTT)
- Comparative Clinical Interpretation of Coagulation Results
- Anticoagulation Reversal Agents
- Anticoagulation Reversal Agents
- Which of the following reversal anticoagulant therapies is appropriate for patients being treated with dabigatran who experience massive bleeding?
- Conclusion
- References
Additional Information
Level of Instruction: Intermediate
Intended Audience: Practicing medical laboratory scientists (MLS), medical laboratory technicians (MLT), MLS students, and MLT students.
Author Information: Mary Louise Turgeon, Ed.D, MLS(ASCP)CM, is the author of four medical laboratory science textbooks: Basic & Applied Clinical Laboratory Science (8 ed), Elsevier(2020); Immunology and Serology in Laboratory Medicine (7 ed), Elsevier (2022); Clinical Hematology (6 ed), Lippincott-Williams & Wilkins (2018); and Fundamentals of Immunohematology 2 ed). Foreign language editions have been published in Chinese, Spanish, and Italian.
Dr. Turgeon has 18 years of university and 15 years of community college teaching and program administration experience. Guest speaking, scientific presentations, and technical and educational workshops complement her teaching and writing activities.
Reviewer Information:
Rory Huschka, M.Ed., MLS(ASCP) is a Content Developer at MediaLab Inc. He holds a BS degree from North Dakota State University in Medical Technology and an MS degree in Educational Leadership. He is a former Program Director for both MLT and MLS programs. Rory continues to teach as an adjunct professor for various colleges and universities.
Laurie Bjerklie, M.Ed., MLS(ASCP) is a Content Developer at MediaLab Inc. She is a former Program Director for MLT and MLS programs and continues to work as an adjunct in various MLT and MLS programs.
Course Description:
This course addresses some of the new oral anticoagulants that are being used and some of the challenges faced when using traditional coagulation tests to assess the drug effects. Strategies for effectively monitoring these new therapeutic drugs along with advantages and disadvantages of their use are discussed.
